Search results
Results From The WOW.Com Content Network
AstraZeneca also developed esomeprazole (Nexium) which is a eutomer, purely the (S)-enantiomer, rather than a racemate like omeprazole. [medical citation needed] Omeprazole undergoes a chiral shift in vivo which converts the inactive (R)-enantiomer to the active (S)-enantiomer, doubling the concentration of the active form. [59]
AstraZeneca plc ( / ˌæstrəˈzɛnəkə /) ( AZ) is a British-Swedish multinational pharmaceutical and biotechnology company [ 2 ][ 3 ][ 4 ] with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. [ 5 ] It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal ...
Esomeprazole is the (S)-(−)-enantiomer (or less specifically the S-isomer) of omeprazole. [11] It works by blocking H + /K +-ATPase in the parietal cells of the stomach. [11] It was patented in 1993 and approved for medical use in 2000. [14] It is available as a generic medication and sold over the counter in a number of countries.
AstraZeneca’s COVID-19 vaccine provided strong protection against sickness and eliminated hospitalizations and deaths from the disease across all age groups in a late-stage study in the United ...
The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease. The drug ...
For premium support please call: 800-290-4726 more ways to reach us
Naproxen/esomeprazole, sold under the brand name Vimovo, is a pain reliever medication in the form of a tablet for oral consumption, containing naproxen, a nonsteroidal anti-inflammatory drug (NSAID), and a delayed release formulation of esomeprazole, a stomach acid–reducing proton-pump inhibitor (PPI). [ 2][ 3] It is produced by AstraZeneca ...
Proton-pump inhibitor. Proton-pump inhibitors ( PPIs) are a class of medications that cause a profound and prolonged reduction of stomach acid production. They do so by irreversibly inhibiting the stomach's H + /K + ATPase proton pump. [1] Proton-pump inhibitors have largely superseded the H 2 -receptor antagonists, a group of medications with ...